Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

H. M. Babiker; I. Brana; D. Mahadevan; T. K. Owonikoko; E. Calvo; D. Rischin; V. Moreno; K. P. Papadopoulos; M. Crittenden; S. Formenti; J. Giralt; P. Garrido Lopez; A. Hervás Morón; K. K. Mohan; M. G. Fury; I. Lowy; E. Stankevich; M. Feng; J. Li; M. Mathias

doi:10.1093/annonc/mdy288.044

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

H. M. Babiker, I. Brana, D. Mahadevan, T. K. Owonikoko, E. Calvo, D. Rischin, V. Moreno, K. P. Papadopoulos, M. Crittenden, S. Formenti, J. Giralt, P. Garrido Lopez, A. Hervás Morón, K. K. Mohan, M. G. Fury, I. Lowy, E. Stankevich, M. Feng, J. Li, M. Mathias

Mays Cancer Center

Research output: Contribution to journal › Article › peer-review

139 Scopus citations

Original language	English (US)
Pages (from-to)	viii418
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy288.044
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy288.044

Cite this

Babiker, H. M., Brana, I., Mahadevan, D., Owonikoko, T. K., Calvo, E., Rischin, D., Moreno, V., Papadopoulos, K. P., Crittenden, M., Formenti, S., Giralt, J., Garrido Lopez, P., Hervás Morón, A., Mohan, K. K., Fury, M. G., Lowy, I., Stankevich, E., Feng, M., Li, J., & Mathias, M. (2018). Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii418. https://doi.org/10.1093/annonc/mdy288.044

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). / Babiker, H. M.; Brana, I.; Mahadevan, D. et al.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii418.

Research output: Contribution to journal › Article › peer-review

Babiker, HM, Brana, I, Mahadevan, D, Owonikoko, TK, Calvo, E, Rischin, D, Moreno, V, Papadopoulos, KP, Crittenden, M, Formenti, S, Giralt, J, Garrido Lopez, P, Hervás Morón, A, Mohan, KK, Fury, MG, Lowy, I, Stankevich, E, Feng, M, Li, J & Mathias, M 2018, 'Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii418. https://doi.org/10.1093/annonc/mdy288.044

Babiker HM, Brana I, Mahadevan D, Owonikoko TK, Calvo E, Rischin D et al. Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii418. https://doi.org/10.1093/annonc/mdy288.044

Babiker, H. M. ; Brana, I. ; Mahadevan, D. et al. / Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii418.

@article{61ca33eb7edb4b38ba6d6551c14d6003,

title = "Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)",

author = "Babiker, {H. M.} and I. Brana and D. Mahadevan and Owonikoko, {T. K.} and E. Calvo and D. Rischin and V. Moreno and Papadopoulos, {K. P.} and M. Crittenden and S. Formenti and J. Giralt and {Garrido Lopez}, P. and {Herv{\'a}s Mor{\'o}n}, A. and Mohan, {K. K.} and Fury, {M. G.} and I. Lowy and E. Stankevich and M. Feng and J. Li and M. Mathias",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy288.044",

language = "English (US)",

volume = "29",

pages = "viii418",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

AU - Babiker, H. M.

AU - Brana, I.

AU - Mahadevan, D.

AU - Owonikoko, T. K.

AU - Calvo, E.

AU - Rischin, D.

AU - Moreno, V.

AU - Papadopoulos, K. P.

AU - Crittenden, M.

AU - Formenti, S.

AU - Giralt, J.

AU - Garrido Lopez, P.

AU - Hervás Morón, A.

AU - Mohan, K. K.

AU - Fury, M. G.

AU - Lowy, I.

AU - Stankevich, E.

AU - Feng, M.

AU - Li, J.

AU - Mathias, M.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081950434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081950434&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy288.044

DO - 10.1093/annonc/mdy288.044

M3 - Article

C2 - 32137049

VL - 29

SP - viii418

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this